UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): March 13, 2020

305 W. Woodard Street, Suite 221, Denison TX 75020

(Address of Principal Executive Offices)

(903) 337-1872

(Registrant’s Telephone number)

Copies to:

Asher S. Levitsky PC

Ellenoff Grossman & Schole LLP

1345 Avenue of the Americas, Suite 1100

New York, New York 10105

Phone: (646) 895-7152

Fax: (646) 895-7238

E-mail: alevitsky@egsllp.com

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐     Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))

☐     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by a check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. ☐

Securities registered pursuant to Section 12(b) of the Act: None

Item 1.01 Entry into a Material Definitive Agreement

On March 13, 2020, the Company’s subsidiary, PreCheck Health Services S.A.S., entered into a distribution agreement dated March 13, 2020, with Co-Diagnostics Inc. pursuant to which Co-Diagnostics granted the Company’s subsidiary the exclusive distribution rights to its qPCR infectious disease kits, Logix Smart COVID-19 PCR diagnostic test and Co-Dx Box™ instrument for Ecuador. The distribution agreement has a term of one year, but can be terminated by either party on 30 days’ notice. The agreement provides that it is the Company’s responsibility to obtain all necessary licenses and permits for the marketing of the product in Ecuador. The Company does not have any offices or facilities in Ecuador and intends to distribute the products through sub-distributors or other representative.

On March 13, 2020, the Company entered into a marketing agreement dated March 12, 2020 with Co-Diagnosis and Health Tech Innovation Systems, Inc., which is the distributor for Co-Diagnostics’ products in Panama. Pursuant to the agreement the Company has the right to purchase Logix Smart COVID-19 PCR diagnostic test and Co-Dx Box instrument from Co-Diagnostics for sale by the Company to its customers in Panama. The Company is to pay Health Tech Innovation Systems a fee in connection with any sales by the Company to its customers in Panama. The marketing agreement has a term of one year, but can be terminated by any party on 30 days’ notice.

The products covered by both agreements are in vitro diagnostic tests, and Co-Diagnostics has reported in its SEC filings that it has received ISO 13485 certification relating to the design and manufacture of its medical device products, and that the ISO certification indicates that it meets the standards required to self-certify certain of its products and affix a CE marking for sales of its products in countries accepting the CE marking (not in the United States) with only minimal further governmental approvals in each country, and its Zika and tuberculosis tests were CE-marked in 2018, its first multiplex test (Zika, Dengue, and Chikungunya) was CE-marked in 2019, and it received a CE mark for its Logix Smart Covid-19 test for corona virus in February 2020.

Item 7.01 Regulation FD Disclosure

On March 13, 2020, the Company issued a press release covering the Ecuador distribution agreement and a purchase order placed by the Company.

In accordance with General Instruction B.2 of Form 8-K, the information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.3, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and regardless of any general incorporation language in such filings, except to the extent expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

________ 

* Confidential information in this agreement has been omitted.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.